Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck NCT05172258 Head and Neck S...
Metastatic Head...
Metastatic Hypo...
Metastatic Lary...
Metastatic Oral...
Metastatic Orop...
Recurrent Head ...
Recurrent Hypop...
Recurrent Laryn...
Recurrent Oral ...
Recurrent Oroph...
Stage IV Hypoph...
Stage IV Laryng...
Stage IV Lip an...
Stage IV Oropha...
Biopsy
Biospecimen Col...
Computed Tomogr...
Ipatasertib
Pembrolizumab
18 Years - National Cancer Institute (NCI) View Fluciclovine F18 PET/CT in Identifying the Origin of Head and Neck Squamous Cell Carcinoma in Patients With Metastatic Cervical Nodal Disease NCT03868020 Metastatic Head...
Metastatic Squa...
Computed Tomogr...
Fluciclovine F1...
Positron Emissi...
18 Years - M.D. Anderson Cancer Center View Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies NCT03590054 Stage III Cutan...
Stage IV Cutane...
Locally Advance...
Locally Advance...
Metastatic Head...
Metastatic Mali...
Metastatic Mela...
Metastatic Urot...
Non-Small Cell ...
Stage IB Lung C...
Stage III Cutan...
Stage III Lung ...
Stage III Urete...
Stage IIIA Lung...
Stage IIIB Lung...
Stage IIIC Lung...
Stage IV Cutane...
Stage IV Lung C...
Stage IV Ureter...
Stage IVA Lung ...
Stage IVB Lung ...
Abexinostat
Pembrolizumab
18 Years - University of California, San Francisco View Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma NCT04643379 Recurrent Head ...
Metastatic Head...
Olaparib
Pembrolizumab
Carboplatin
Peripheral bloo...
18 Years - Washington University School of Medicine View Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma NCT06211335 Locally Recurre...
Metastatic Head...
Refractory Head...
Losartan
Pembrolizumab
Stereotactic Bo...
18 Years - University of California, Davis View Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma NCT04643379 Recurrent Head ...
Metastatic Head...
Olaparib
Pembrolizumab
Carboplatin
Peripheral bloo...
18 Years - Washington University School of Medicine View Phase II Trial of Pembrolizumab in Recurrent or Metastatic HNSCC NCT03813836 Metastatic Head...
Recurrent Head ...
Pembrolizumab
18 Years - University College, London View Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery NCT01468896 Metastatic Head...
Recurrent Head ...
Unresectable He...
Cetuximab
Edodekin alfa
Laboratory Biom...
18 Years - National Cancer Institute (NCI) View Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma NCT03498378 Head and Neck S...
Avelumab
Palbociclib
Cetuximab
18 Years - University of California, San Diego View Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer NCT00494182 Metastatic Head...
Metastatic Squa...
Metastatic Squa...
Metastatic Squa...
Metastatic Squa...
Recurrent Head ...
Recurrent Hypop...
Recurrent Laryn...
Recurrent Oral ...
Recurrent Oroph...
Carboplatin
Paclitaxel
Sorafenib
18 Years - M.D. Anderson Cancer Center View INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma NCT05359692 Metastatic Head...
Advanced Malign...
Recurrent Head ...
INCAGN01876
retifanlimab
18 Years - 99 Years Incyte Corporation View Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat NCT03823131 Metastatic Head...
Recurrent Head ...
Unresectable He...
ImmunoPulse
Epacadostat
Pembrolizumab
CORVax
Tavokinogene te...
18 Years - University of California, San Francisco View Standard and Delayed FDG PET/CT After Chemoradiation Therapy in Assessing Patients With Metastatic Head and Neck Squamous Cell Cancer NCT03575949 Metastatic Head...
Metastatic Mali...
Computed Tomogr...
Fludeoxyglucose...
Positron Emissi...
18 Years - M.D. Anderson Cancer Center View Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma NCT06211335 Locally Recurre...
Metastatic Head...
Refractory Head...
Losartan
Pembrolizumab
Stereotactic Bo...
18 Years - University of California, Davis View Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program NCT06265285 Advanced Esopha...
Advanced Renal ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Esophageal Carc...
Gastroesophagea...
Hepatocellular ...
Locally Advance...
Lung Non-Small ...
Malignant Solid...
Metastatic Colo...
Metastatic Cuta...
Metastatic Esop...
Metastatic Head...
Metastatic Urot...
Recurrent Esoph...
Recurrent Head ...
Renal Cell Carc...
Stage III Renal...
Stage IV Colore...
Stage IV Cutane...
Stage IV Renal ...
Unresectable Cu...
Unresectable Es...
Urothelial Carc...
Home Health Enc...
Nivolumab
Patient Monitor...
Questionnaire A...
18 Years - Mayo Clinic View Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma NCT03522584 Metastatic Head...
Recurrent Head ...
Durvalumab
Laboratory Biom...
Stereotactic Bo...
Tremelimumab
Hypofractionate...
18 Years - University of Washington View Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors NCT04007744 Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Locally Advance...
Locally Advance...
Locally Advance...
Metastatic Gast...
Metastatic Gast...
Metastatic Head...
Metastatic Lung...
Metastatic Mali...
Metastatic Mela...
Metastatic Urot...
Recurrent Head ...
Refractory Lung...
Stage IV Cutane...
Stage IV Lung C...
Unresectable Ma...
Unresectable Me...
Pembrolizumab
Sonidegib
18 Years - Mayo Clinic View Phase II Trial of Pembrolizumab in Recurrent or Metastatic HNSCC NCT03813836 Metastatic Head...
Recurrent Head ...
Pembrolizumab
18 Years - University College, London View Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck NCT04862650 Clinical Stage ...
Metastatic Head...
Metastatic Hypo...
Metastatic Lary...
Metastatic Oral...
Metastatic Orop...
Pathologic Stag...
Recurrent Head ...
Recurrent Hypop...
Recurrent Laryn...
Recurrent Oral ...
Recurrent Oroph...
Squamous Cell C...
Stage IV Hypoph...
Stage IV Laryng...
Stage IV Lip an...
Stage IVA Hypop...
Stage IVA Laryn...
Stage IVA Lip a...
Stage IVB Hypop...
Stage IVB Laryn...
Stage IVB Lip a...
Stage IVC Hypop...
Stage IVC Laryn...
Stage IVC Lip a...
Carboplatin
Cemiplimab
Paclitaxel
18 Years - Ohio State University Comprehensive Cancer Center View Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck NCT05172258 Head and Neck S...
Metastatic Head...
Metastatic Hypo...
Metastatic Lary...
Metastatic Oral...
Metastatic Orop...
Recurrent Head ...
Recurrent Hypop...
Recurrent Laryn...
Recurrent Oral ...
Recurrent Oroph...
Stage IV Hypoph...
Stage IV Laryng...
Stage IV Lip an...
Stage IV Oropha...
Biopsy
Biospecimen Col...
Computed Tomogr...
Ipatasertib
Pembrolizumab
18 Years - National Cancer Institute (NCI) View (89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma NCT05747625 Head and Neck S...
Metastatic Head...
Stage IV Cutane...
Panitumumab
Zirconium Zr 89...
Positron Emissi...
Computed Tomogr...
Electronic Heal...
19 Years - Vanderbilt-Ingram Cancer Center View Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck NCT04862650 Clinical Stage ...
Metastatic Head...
Metastatic Hypo...
Metastatic Lary...
Metastatic Oral...
Metastatic Orop...
Pathologic Stag...
Recurrent Head ...
Recurrent Hypop...
Recurrent Laryn...
Recurrent Oral ...
Recurrent Oroph...
Squamous Cell C...
Stage IV Hypoph...
Stage IV Laryng...
Stage IV Lip an...
Stage IVA Hypop...
Stage IVA Laryn...
Stage IVA Lip a...
Stage IVB Hypop...
Stage IVB Laryn...
Stage IVB Lip a...
Stage IVC Hypop...
Stage IVC Laryn...
Stage IVC Lip a...
Carboplatin
Cemiplimab
Paclitaxel
18 Years - Ohio State University Comprehensive Cancer Center View Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery NCT01468896 Metastatic Head...
Recurrent Head ...
Unresectable He...
Cetuximab
Edodekin alfa
Laboratory Biom...
18 Years - National Cancer Institute (NCI) View Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers NCT05063552 Clinical Stage ...
Metastatic Head...
Metastatic Hypo...
Metastatic Lary...
Metastatic Lip ...
Metastatic Nasa...
Metastatic Naso...
Metastatic Phar...
Metastatic Sino...
Recurrent Head ...
Recurrent Hypop...
Recurrent Laryn...
Recurrent Lip a...
Recurrent Nasop...
Recurrent Phary...
Recurrent Sinon...
Stage IV Hypoph...
Stage IV Laryng...
Stage IV Lip an...
Stage IV Nasoph...
Stage IV Oropha...
Stage IV Sinona...
Atezolizumab
Bevacizumab
Biospecimen Col...
Carboplatin
Cetuximab
Cisplatin
Computed Tomogr...
Docetaxel
Echocardiograph...
Magnetic Resona...
Positron Emissi...
18 Years - National Cancer Institute (NCI) View INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma NCT05359692 Metastatic Head...
Advanced Malign...
Recurrent Head ...
INCAGN01876
retifanlimab
18 Years - 99 Years Incyte Corporation View Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC NCT05156970 Recurrent Head ...
Metastatic Head...
Camrelizumab
Cisplatin
Docetaxel
Apatinib Mesyla...
Carboplatin
18 Years - 75 Years Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University View Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors NCT04007744 Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Locally Advance...
Locally Advance...
Locally Advance...
Metastatic Gast...
Metastatic Gast...
Metastatic Head...
Metastatic Lung...
Metastatic Mali...
Metastatic Mela...
Metastatic Urot...
Recurrent Head ...
Refractory Lung...
Stage IV Cutane...
Stage IV Lung C...
Unresectable Ma...
Unresectable Me...
Pembrolizumab
Sonidegib
18 Years - Mayo Clinic View Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program NCT06265285 Advanced Esopha...
Advanced Renal ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Esophageal Carc...
Gastroesophagea...
Hepatocellular ...
Locally Advance...
Lung Non-Small ...
Malignant Solid...
Metastatic Colo...
Metastatic Cuta...
Metastatic Esop...
Metastatic Head...
Metastatic Urot...
Recurrent Esoph...
Recurrent Head ...
Renal Cell Carc...
Stage III Renal...
Stage IV Colore...
Stage IV Cutane...
Stage IV Renal ...
Unresectable Cu...
Unresectable Es...
Urothelial Carc...
Home Health Enc...
Nivolumab
Patient Monitor...
Questionnaire A...
18 Years - Mayo Clinic View Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC NCT05156970 Recurrent Head ...
Metastatic Head...
Camrelizumab
Cisplatin
Docetaxel
Apatinib Mesyla...
Carboplatin
18 Years - 75 Years Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University View A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma NCT04196283 Advanced Solid ...
ABBV-368
Tilsotolimod
Nab-paclitaxel
ABBV-181
18 Years - AbbVie View